Details of the Drug Reposition

General Information of This Drug (ID: DMN5T2A)

• Drug Name: Ciclopirox (DMN5T2A)
• Synonyms: Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

6 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pityriasis simplex	DIS1K9V6	N.A.	Approved	[1]
Cutaneous candidiasis	DIS2U1JN	1F23.14	Approved	[1]
Tinea cruris	DIS5JC14	1F28.3	Approved	[1]
Tinea versicolor	DIS5VG35	1F2D.0	Approved	[1]
Mycoses	DIS9K7PB	1F2Z	Approved	[1]
Onychomycosis	DISE4C4D	EE12.1	Approved	[1]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Seborrhoeic dermatitis	DISNWVJU	EA81	Discontinued in Phase 2	[2]

References

• [1] Ciclopirox FDA Label
• [2] Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer